Cellular reprogramming: A novel tool for investigating autism spectrum disorders

Trends in Molecular Medicine

Volumn 18, Issue 8, 2012, Pages 463-471

  Kim, Kun Yong ^a   Jung, Yong Wook ^a,b   Sullivan, Gareth J ^c,d   Chung, Leeyup ^e   Park, In Hyun ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHA University   (South Korea)

^c UNIVERSITY OF OSLO   (Norway)

^d Norwegian Center for Stem Cell Research   (Norway)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autism spectrum disorder; Disease modeling; Fragile X syndrome; Induced pluripotent stem cells; Neurodevelopmental disorder; Reprogramming; Rett syndrome; Timothy syndrome

Indexed keywords

ESTERASE; METHYL CPG BINDING PROTEIN 2; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; UNCLASSIFIED DRUG; ZINC FINGER NUCLEASE;

AUTISM; CELL RENEWAL; CELL REPROGRAMMING; CELL THERAPY; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CHROMOSOME ANALYSIS; COPY NUMBER VARIATION; CYTOGENETICS; DISEASE MODEL; FRAGILE X SYNDROME; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC DISORDER; GENOMICS; HAPPY PUPPET SYNDROME; HUMAN; MISSENSE MUTATION; PLURIPOTENT STEM CELL; PRADER WILLI SYNDROME; RETT SYNDROME; REVIEW; SCHIZOPHRENIA; TIMOTHY SYNDROME;

ANIMALS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, BIOLOGICAL;

MURINAE; PHLEUM PRATENSE;

EID: 84864395691     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.06.002     Document Type: Review

References (105)

1. Burd L., et al. A prevalence study of pervasive developmental disorders in North Dakota. J. Am. Acad. Child Adolesc. Psychiatry 1987, 26:700-703.
2. Kogan M.D., et al. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 2009, 124:1395-1403.
3. Bailey A., et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol. Med. 1995, 25:63-77.
4. Steffenburg S., et al. A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. J. Child Psychol. Psychiatry Allied Disciplines 1989, 30:405-416.
5. Folstein S.E., Rosen-Sheidley B. Genetics of autism: complex aetiology for a heterogeneous disorder. Nat. Rev. Genet. 2001, 2:943-955.
6. Abrahams B.S., Geschwind D.H. Advances in autism genetics: on the threshold of a new neurobiology. Nat. Rev. Genet. 2008, 9:341-355.
7. Blenner S., et al. Diagnosis and management of autism in childhood. BMJ 2011, 343:d6238.
8. Moy S.S., Nadler J.J. Advances in behavioral genetics: mouse models of autism. Mol. Psychiatry 2008, 13:4-26.
9. Robertson H.R., Feng G. Annual Research Review: Transgenic mouse models of childhood-onset psychiatric disorders. J. Child Psychol. Psychiatry 2011, 52:442-475.
10. Voineagu I., et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 2011, 474:380-384.
11. Rakic P. Evolution of the neocortex: a perspective from developmental biology. Nat. Rev. Neurosci. 2009, 10:724-735.
12. Evans M.J., Kaufman M.H. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981, 292:154-156.
13. Martin G.R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl. Acad. Sci. U.S.A. 1981, 78:7634-7638.
14. Keirstead H.S., et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J. Neurosci. 2005, 25:4694-4705.
15. Laflamme M.A., et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 2007, 25:1015-1024.
16. Yang D., et al. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells 2008, 26:55-63.
17. Lamba D.A., et al. Transplantation of human embryonic stem cell-derived photoreceptors restores some visual function in Crx-deficient mice. Cell Stem Cell 2009, 4:73-79.
18. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
19. Takahashi K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
20. Park I.H., et al. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
21. Ebert A.D., et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457:277-280.
22. Soldner F., et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009, 136:964-977.
23. Wernig M., et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:5856-5861.
24. Raya A., et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009, 460:53-59.
25. Ye L., et al. Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9826-9830.
26. Swijnenburg R.J., et al. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:12991-12996.
27. Tchieu J., et al. Female human iPSCs retain an inactive X chromosome. Cell Stem Cell 2010, 7:329-342.
28. Kim K.Y., et al. Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14169-14174.
29. Ananiev G., et al. Isogenic pairs of wild type and mutant induced pluripotent stem cell (iPSC) lines from Rett syndrome patients as in vitro disease model. PLoS ONE 2011, 6:e25255.
30. Cheung A.Y., et al. Isolation of MECP2-null Rett syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. Hum. Mol. Genet. 2011, 3:3.
31. Pomp O., et al. Unexpected X chromosome skewing during culture and reprogramming of human somatic cells can be alleviated by exogenous telomerase. Cell Stem Cell 2011, 9:156-165.
32. Mekhoubad S., et al. Erosion of dosage compensation impacts human iPSC disease modeling. Cell Stem Cell 2012, 10:595-609.
33. Lombardo A., et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 2007, 25:1298-1306.
34. Just M.A., et al. Functional and anatomical cortical underconnectivity in autism: evidence from an FMRI study of an executive function task and corpus callosum morphometry. Cereb. Cortex 2007, 17:951-961.
35. Magdaleno S., et al. Rescue of ataxia and preplate splitting by ectopic expression of Reelin in reeler mice. Neuron 2002, 33:573-586.
36. Hansen D.V., et al. Deriving excitatory neurons of the neocortex from pluripotent stem cells. Neuron 2011, 70:645-660.
37. Eiraku M., et al. Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. Cell Stem Cell 2008, 3:519-532.
38. Chambers S.M., et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 2009, 27:275-280.
39. Shi Y., et al. Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat. Neurosci. 2012, 15:477-486. S471.
40. Sykes N.H., et al. Copy number variation and association analysis of SHANK3 as a candidate gene for autism in the IMGSAC collection. Eur. J. Hum. Genet. 2009, 17:1347-1353.
41. Szatmari P., et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat. Genet. 2007, 39:319-328.
42. Cooper G.M., et al. A copy number variation morbidity map of developmental delay. Nat. Genet. 2011, 43:838-846.
43. Weiss L.A., et al. A genome-wide linkage and association scan reveals novel loci for autism. Nature 2009, 461:802-808.
44. State M.W., Levitt P. The conundrums of understanding genetic risks for autism spectrum disorders. Nat. Neurosci. 2011, 14:1499-1506.
45. Toro R., et al. Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet. 2010, 26:363-372.
46. Jamain S., et al. Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:1710-1715.
47. Bangash M.A., et al. Enhanced polyubiquitination of Shank3 and NMDA receptor in a mouse model of autism. Cell 2011, 145:758-772.
48. Penagarikano O., et al. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell 2011, 147:235-246.
49. Hotta A., et al. Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. Nat. Methods 2009, 6:370-376.
50. Marchetto M.C., et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010, 143:527-539.
51. Chen R.Z., et al. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 2001, 27:327-331.
52. Armstrong D.D. Neuropathology of Rett syndrome. J. Child Neurol. 2005, 20:747-753.
53. Farra N., et al. Rett syndrome induced pluripotent stem cell-derived neurons reveal novel neurophysiological alterations. Mol. Psychiatry 2012, 10.1038/mp.2011.180.
54. Ballas N., et al. Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nat. Neurosci. 2009, 12:311-317.
55. Derecki N.C., et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 2012, 484:105-109.
56. Feng Y., et al. Translational suppression by trinucleotide repeat expansion at FMR1. Science 1995, 268:731-734.
57. Eiges R., et al. Developmental study of Fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 2007, 1:568-577.
58. Sutcliffe J.S., et al. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum. Mol. Genet. 1992, 1:397-400.
59. Sheridan S.D., et al. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS ONE 2011, 6:e26203.
60. Urbach A., et al. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 2010, 6:407-411.
61. Michalon A., et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012, 74:49-56.
62. Pasca S.P., et al. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat. Med. 2011, 17:1657-1662.
63. Yazawa M., et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011, 471:230-234.
64. Rapoport J., et al. Autism spectrum disorders and childhood-onset schizophrenia: clinical and biological contributions to a relation revisited. J. Am. Acad. Child Adolesc. Psychiatry 2009, 48:10-18.
65. Sullivan P.F., et al. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry 2003, 60:1187-1192.
66. Idol J.R., et al. Sequencing and analyzing the t(1;7) reciprocal translocation breakpoints associated with a case of childhood-onset schizophrenia/autistic disorder. J. Autism Dev. Disord. 2008, 38:668-677.
67. Addington A.M., et al. A novel frameshift mutation in UPF3B identified in brothers affected with childhood onset schizophrenia and autism spectrum disorders. Mol. Psychiatry 2011, 16:238-239.
68. Brennand K.J., et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011, 473:221-225.
69. Pedrosa E., et al. Development of patient-specific neurons in schizophrenia using induced pluripotent stem cells. J. Neurogenet. 2011, 25:88-103.
70. Chiang C.H., et al. Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. Mol. Psychiatry 2011, 16:358-360.
71. Hu B.Y., et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:4335-4340.
72. Rhee Y.H., et al. Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. J. Clin. Invest. 2011, 121:2326-2335.
73. Kaji K., et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009, 458:771-775.
74. Kim D., et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009, 4:472-476.
75. Deng J., et al. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat. Biotechnol. 2009, 27:353-360.
76. Anokye-Danso F., et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011, 8:376-388.
77. Bock C., et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 2011, 144:439-452.
78. Loh Y.H., et al. Generation of induced pluripotent stem cells from human blood. Blood 2009, 113:5476-5479.
79. Haase A., et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 2009, 5:434-441.
80. Liu H., et al. Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. Hepatology 2010, 51:1810-1819.
81. Aasen T., et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat. Biotechnol. 2008, 26:1276-1284.
82. Polo J.M., et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 2010, 28:848-855.
83. Kim K., et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010, 467:285-290.
84. Taapken S.M., et al. Karotypic abnormalities in human induced pluripotent stem cells and embryonic stem cells. Nat. Biotechnol. 2011, 29:313-314.
85. Martins-Taylor K., et al. Recurrent copy number variations in human induced pluripotent stem cells. Nat. Biotechnol. 2011, 29:488-491.
86. Vierbuchen T., et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010, 463:1035-1041.
87. Pang Z.P., et al. Induction of human neuronal cells by defined transcription factors. Nature 2011, 476:220-223.
88. Lujan E., et al. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2527-2532.
89. Han D.W., et al. Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell Stem Cell 2012, 10:465-472.
90. Thier M., et al. Direct conversion of fibroblasts into stably expandable neural stem cells. Cell Stem Cell 2012, 10:473-479.
91. Falk A., et al. Capture of neuroepithelial-like stem cells from pluripotent stem cells provides a versatile system for in vitro production of human neurons. PLoS ONE 2012, 7:e29597.
92. Lengner C.J., et al. Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Cell 2010, 141:872-883.
93. Diaz Perez S.V., et al. Derivation of new human embryonic stem cell lines reveals rapid epigenetic progression in vitro that can be prevented by chemical modification of chromatin. Hum. Mol. Genet. 2012, 21:751-764.
94. Jamain S., et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat. Genet. 2003, 34:27-29.
95. Klauck S.M., et al. Mutations in the ribosomal protein gene RPL10 suggest a novel modulating disease mechanism for autism. Mol. Psychiatry 2006, 11:1073-1084.
96. Bibikova M., et al. Enhancing gene targeting with designed zinc finger nucleases. Science 2003, 300:764.
97. Brunet E., et al. Chromosomal translocations induced at specified loci in human stem cells. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:10620-10625.
98. Christian M., et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 2010, 186:757-761.
99. Hockemeyer D., et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 2011, 29:731-734.
100. Miller J.C., et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 2011, 29:143-148.
101. Mussolino C., et al. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 2011, 39:9283-9293.
102. Li X.J., et al. Coordination of sonic hedgehog and Wnt signaling determines ventral and dorsal telencephalic neuron types from human embryonic stem cells. Development 2009, 136:4055-4063.
103. Amenduni M., et al. iPS cells to model CDKL5-related disorders. Eur. J. Hum. Genet. 2011, 19:1246-1255.
104. Yang J., et al. Induced pluripotent stem cells can be used to model the genomic imprinting disorder Prader-Willi syndrome. J. Biol. Chem. 2010, 285:40303-40311.
105. Chamberlain S.J., et al. Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:17668-17673.